Julie Horton
Family · Decatur, TNNPI 1437594983
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,688 of the $110,966 with a category attached, or 77.2%. Otsuka America Pharmaceutical, Inc. accounts for 96.8% of it on its own, with 16 other manufacturers making up the rest. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $300.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$107K
- Acadia Pharmaceuticals Inc$1K
- Viiv Healthcare Company$699
- Otsuka Pharmaceutical Development & Commercialization, Inc.$230
- Insmed, Inc.$227
- Johnson & Johnson$160
- plus $698 from 11 others
What the payments were for
- Speaking & faculty fees$85,68877%
- Travel & lodging$19,10217%
- Food & beverage$6,1186%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 249 | $107,462 |
| Acadia Pharmaceuticals Inc | 18 | $1,491 |
| Viiv Healthcare Company | 61 | $699 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $230 |
| Insmed, Inc. | 13 | $227 |
| Johnson & Johnson(2 entities) | 2 | $160 |
| Lundbeck LLC | 1 | $148 |
| Amgen | 2 | $120 |
| Neurocrine Biosciences, Inc. | 1 | $97 |
| GSK | 5 | $78 |
| Mylan Specialty L.p. | 2 | $64 |
| Paratek Pharmaceuticals, Inc. | 2 | $49 |
| Novo Nordisk | 2 | $45 |
| Bayer | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Seqirus USA Inc | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$103,655
- NUPLAZID$1,054
- INVEGA SUSTENNA$140
- Otezla$104
How this compares
$110,966 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 20 | $31,117 |
| Duloxetine Hcl | 14 | $417 |
| Trazodone Hcl | 32 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $107,462 | $31,11720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Decatur
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.